Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
Last trade$14.95
Day change-$0.385 (-2.51%)
Day range$14.64 – $16.23
Volume1,364,622
Market cap$1.06B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.06B
Price / earnings
—
Price / book
2.41×
Price / sales
—
EV / sales
—
EV / EBITDA
-6.06×
Profitability
Earnings per share
-$1.78
Return on assets
-26.05%
Return on equity
-27.96%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
14.93×
Quick ratio
14.93×
Cash ratio
3.4×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$110.21M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for JBIO, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Revenue
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
Selling, general and administrative
$8.85M
$7.39M
$5.39M
$5.23M
Research and development
$50.07M
$36.05M
$22.01M
$22.55M
Total operating expenses
$58.92M
$43.45M
$27.4M
$27.78M
Operating income
-$58.92M
-$43.45M
-$27.4M
-$27.78M
Interest expense
$3.23M
$3.1M
$0
$1.83M
Income before taxes
-$55.75M
-$40.35M
-$25.18M
-$32.13M
Income taxes
$15K
$16K
$0
$0
Net income
-$55.77M
-$40.37M
-$25.18M
-$32.13M
Net income attributable to common shareholders
-$46.21M
-$33.13M
-$19.09M
-$24.55M
EBITDA
-$58.91M
-$43.44M
-$27.39M
-$27.77M
Basic earnings per share
-$0.76
-$0.57
-$0.48
-$0.86
Diluted earnings per share
-$0.76
-$0.57
-$0.48
-$0.86
Recent news
Company coverage with links to the original publishers.
Jade Biosciences, Inc. (Nasdaq: JBIO) announced the appointment of Dr. Mark Eisner, M.D., M.P.H., to its Board of Directors effective June 25, 2026. Dr. Eisner brings over 25 years of leadership experience in clinical development and immunology, including previous roles as Chief Medical Officer at Vir Biotechnology, Sonoma Biotherapeutics, and FibroGen, as well as 11 years at Genentech/Roche. The appointment is expected to strengthen Jade's advancement of its pipeline of antibody-based therapies for autoimmune diseases.
U.S. stock futures showed mixed performance on Thursday with the S&P 500 and Nasdaq 100 declining while the Dow Jones gained. Key movers included CrowdStrike surging on a 4-for-1 stock split announcement, Broadcom falling despite beating earnings estimates, and PVH plummeting after disappointing guidance. The House passed a war powers resolution challenging Trump's military authority in a rare bipartisan vote. BlackRock maintains an optimistic outlook on U.S. equities driven by AI sector strength and resilient corporate earnings.
Jade Biosciences (Nasdaq: JBIO), a clinical-stage biotech company focused on autoimmune diseases, announced the pricing of a public offering of 10 million shares at $15.00 per share, raising $150 million in gross proceeds. The offering is expected to close on June 5, 2026, with net proceeds to be used for clinical trials, preclinical studies, manufacturing, and R&D activities. Jefferies, TD Cowen, and UBS Investment Bank are serving as joint book-running managers.
Jade Biosciences reported positive interim Phase 1 results for JADE101, an anti-APRIL monoclonal antibody for IgA nephropathy treatment. The drug demonstrated ~70% IgA reductions sustained at 12 weeks with a favorable safety profile and potential for every-12-week dosing. Phase 2 trials are underway with Phase 3 expected to initiate in H1 2027.
Jade Biosciences announced the appointment of Edward R. Conner, M.D., as Chief Medical Officer effective April 22, 2026. As part of the appointment, Dr. Conner received 500,000 non-qualified stock options with an exercise price of $25.38 per share, vesting over four years. The company is a clinical-stage biotech focused on autoimmune disease therapies with lead candidate JADE101 targeting APRIL for immunoglobulin A nephropathy treatment.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.